Related Experiment Video
Updated: May 14, 2026
12:10
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
Global research trends in single-port robot-assisted radical prostatectomy: a visualization-based bibliometric
Gen Fan1, Haochuan Chen2, Yushui Chen1
1Department of Urology, School of Clinical Medicine, North Sichuan Medical College, Affiliated Hospital of North Sichuan Medical College, No. 1, South Maoyuan Road, Shunqing District, Nanchong, 63700, Sichuan, China.
Journal of Robotic Surgery
|May 13, 2026
Summary
Research on single-port robot-assisted radical prostatectomy (SP-RARP) is rapidly growing, with a focus shifting to outcomes and perioperative care. More clinical trials are needed to confirm long-term benefits.
Area of Science:
- Urology
- Surgical Robotics
- Bibliometrics
Background:
- Single-port robot-assisted radical prostatectomy (SP-RARP) represents an evolving minimally invasive surgical technique.
- Understanding research trends is crucial for advancing SP-RARP applications in prostate cancer treatment.
Purpose of the Study:
- To systematically analyze research hotspots and trends in SP-RARP using bibliometric methods.
- To identify key contributors, collaborations, and evolving research themes in the field.
Main Methods:
- Bibliometric analysis of 271 publications from 2008-2025 sourced from the Web of Science Core Collection.
- Co-occurrence network visualization and cluster analysis of countries, institutions, scholars, journals, and keywords.
Main Results:
- Publication volume increased significantly post-2019, with a citation peak in 2025.
- The United States and Italy lead in publications and collaborations; China, UK, South Korea, and France show notable activity.
- Research focus shifted from feasibility to complication control, functional outcomes, and perioperative care.
Conclusions:
- SP-RARP offers expanded minimally invasive treatment strategies for prostate cancer with potential for improved outcomes.
- Further high-quality clinical trials are essential to validate long-term oncological and functional benefits amidst technological advancements.
